Skip to main content
Premium Trial:

Request an Annual Quote

Sequenom Sells $7M in MassARRAYs to Samsung in Diagnostics-Discovery Deal

NEW YORK, June 18 - Sequenom today said it sold "multiple" units of its MassARRAY gene-analysis tools to Korean conglomerate Samsung to help it discover diagnostics.
Terms of the agreement call for Sequenom to receive 50 percent of the rights to any drugs developed from genes discovered by the Samsung Advanced Institute of Technology. The genomic tool shop will also receiv a 5-percent royalty on any diagnostic tests Samsung develops using the technology.

Though no other financial details were released, Reuters reported this morning that Samsung bought $7 million worth of the MassARRAY tools. This figure could not be independently verified.


Click here for more information.

The Scan

Harvard Team Report One-Time Base Editing Treatment for Motor Neuron Disease in Mice

A base-editing approach restored SMN levels and improved motor function in a mouse model of spinal muscular atrophy, a new Science paper reports.

International Team Examines History of North American Horses

Genetic and other analyses presented in Science find that horses spread to the northern Rockies and Great Plains by the first half of the 17th century.

New Study Examines Genetic Dominance Within UK Biobank

Researchers analyze instances of genetic dominance within UK Biobank data, as they report in Science.

Cell Signaling Pathway Identified as Metastasis Suppressor

A new study in Nature homes in on the STING pathway as a suppressor of metastasis in a mouse model of lung cancer.